Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $152.35 USD
Change Today -0.08 / -0.05%
Volume 993.7K
BDX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

becton dickinson and co (BDX) Key Developments

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2015

Becton, Dickinson and Company has declared a quarterly dividend of 60 cents per common share, payable on September 30, 2015 to holders of record on September 9, 2015. The indicated annual dividend rate is $2.40 per share.

Becton, Dickinson and Company Opens Advance Diabetes Care Facility in Andover, Massachusetts

Becton, Dickinson and Company announced that it has opened its Advanced Diabetes Care facility in Andover, Mass., which will house research and development (R&D) and manufacturing of novel solutions for Type 1 and Type 2 diabetes. The Andover facility, which will serve as the new headquarters for BD's Advanced Diabetes Care platform, incorporates a 'Center of Excellence' model, bringing R&D and manufacturing of solutions for Type 1 and Type 2 diabetes patients under one roof. Approximately 100 associates will be located in the 75,000 square foot facility.

Becton Dickinson and Guidepoint Help Startups Connect to Experts

Becton Dickinson and Guidepoint announced that they are partnering to help provide Guidepoint's expert network services to select healthcare startups. Through the arrangement, Guidepoint will arrange consultations between selected healthcare entrepreneurs and experts in their fields.

BD Introduces Two Prefilled Drug Delivery Systems in India

BD has introduced two prefilled drug delivery systems in India. These systems are expected to help minimize vaccine wastage, reduce dosage errors and impact public health by enabling therapy compliance for patients Two new prefilled drug delivery devices - one for chronic diseases and another for vaccination were introduced at Technovation 2015 by BD Medical - Pharmaceutical Systems. BD Neopak is a single-dose, ready-to-use glass prefillable syringe system. It is an advanced version of normal prefillable syringe, particularly suitable for biotech drugs, that are more sensitive in nature and require delivery devices ensuring virtually no interaction and aggregation with the drug. Reportedly, BD Neopak offers additional benefits of PFS such as lesser injection time, lesser errors, reduced contamination and much better productivity to patients and clinicians. BD Uniject SCF is a single-use prefilled auto disable injection system that protects against inappropriate needle reuse. Being tamper proof, this system can be used even by healthcare workers, for greater coverage of outreach programs such as mass immunization. Both forms of drug delivery is expected to assist the process of administering pharma compounds to achieve desired effect far more quickly and effectively.

BD Medical and Medtronic Collaborate to Introduce New Infusion Set

BD Medical and Medtronic announced a collaboration to introduce a new insulin pump infusion set with BD FlowSmart technology. An insulin infusion set delivers insulin from the pump to the body and is a critical part of the overall pump system. As part of the agreement, Medtronic will commercialize the infusion set, while BD will manufacture the product. This agreement represents an important collaboration between two diabetes device companies uniting to address unmet needs and improve infusion set options for people with diabetes using insulin pumps. The infusion set received both FDA clearance (April 2015) and Health Canada approval (January 2015) and is expected to be launched in 2016. The insulin infusion set with BD FlowSmart technology features a unique side-ported catheter designed to improve insulin flow, potentially reducing the number of flow interruptions – defined as a continuous rise in inline pressure lasting at least 30 minutes. Without triggering a pump occlusion alarm, these events are known as silent occlusions, and because pump users may be unaware of these lapses in insulin flow, they could lead to unexplained hyperglycemia in some people on pump therapy. This infusion set also features the smallest insertion needle (30 gauge) currently available, which is designed to reduce insertion pain.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDX:US $152.35 USD -0.08

BDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,980 JPY +5.00
Avago Technologies Ltd $123.47 USD -2.33
Boston Scientific Corp $17.09 USD -0.02
Mylan NV $54.67 USD -0.53
Stryker Corp $101.48 USD -0.03
View Industry Companies
 

Industry Analysis

BDX

Industry Average

Valuation BDX Industry Range
Price/Earnings 28.0x
Price/Sales 3.5x
Price/Book 4.5x
Price/Cash Flow 29.6x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BECTON DICKINSON AND CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.